Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors

CONCLUSIONS: Overall, there was no difference in PFS between octreotide LAR and somatuline depot for pts with well-differentiated, metastatic GEP-NETs. A prospective study is worth designing selecting for G.PMID:35078191 | DOI:10.1159/000519605

Source: Oncology - January 25, 2022 Category: Cancer & Oncology Authors: Mohammed B Allaw Jeffrey M Switchenko Lana Khalil Christina Wu Olatunji B Alese Mehmet Akce Amber Draper Aaron T Jones Bassel El-Rayes Walid Shaib Source Type: research